Drug Approval | 18 September 2021
Zydus Cadila receives final nod for anti-depressant
The medicine helps restore the balance of certain natural substances (serotonin) in the brain
The medicine helps restore the balance of certain natural substances (serotonin) in the brain
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21
The first lot of IPV will be supplied to the government this month as per the requirement of the Health Ministry
.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The medicine is now approved for eight indications across five different types of cancer in China.
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained
It is the first-ever approval in India for the treatment of Female Pattern Hair Loss (FPHL) and will be available only on prescription by a dermatologist
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The trial will be conducted across eight sites in Maharashtra
Subscribe To Our Newsletter & Stay Updated
